Skip to main content
. 2018 Apr 23;2(8):923–932. doi: 10.1182/bloodadvances.2018016121

Table 2.

Outcome analysis

Characteristic All patients (N = 655) Relapsed AML (n = 365) Refractory AML (n = 290) Bridging to alloSCT (n = 63) P
Response (n = 638), n (%) Relapsed vs refractory = .0248, alloSCT vs no alloSCT < .0001
 CR 70 (11) 41 (11.6) 29 (10.2) 18 (28.6)
 CRi 34 (5.3) 25 (7.1) 9 (3.2) 15 (23.8)
 HI 54 (8.5) 21 (5.9) 33 (11.6) 2 (3.2)
 SD 47 (7.4) 24 (6.8) 23 (8.1) 8 (12.7)
 PD 433 (67.9) 242 (68.6) 191 (67.0) 20 (31.7)
OS based on response (n = 621), median (95% CI), mo 6.7 (6.1-7.3) 6.2 (5.6-7.4) 7 (6.4-8.9) 12.5 (9.7-17) Relapsed vs refractory = .47, alloSCT vs no alloSCT < 0.0001
 CR 25.3 (17-30.2) 23.9 (16.8-46.2) 25.3 (16.7-Inf) 17.7 (15.3-Inf)
 CRi 14.6 (9.5-32) 11.7 (9.5-Inf) 16.1 (8.9-Inf) 11.7 (9.5-Inf)
 HI 11.7 (9.4-14.6) 9.4 (7.8-46.5) 11.7 (9.7-14.9) 9.4 (NA)
 SD 10.4 (8.7-14) 8.7 (5.8-16.4) 10.6 (9.1-17.7) 16.4 (10.6-Inf)
 PD 4.5 (4.1-5.3) 4.7 (3.9-5.6) 4.4 (3.8-5.9) 6.7 (4.5-16.6)
OS based on HMA used (n = 621), median (95% CI), mo
 Azacitidine 6.8 (6-8.5) 6.3 (5.3-8.4) 7.5 (6.5-9.4) 16.1 (9.5-Inf) Relapsed vs refractory = 0.532, alloSCT vs no alloSCT = 0.0237
 Decitabine 6.2 (5.3-7.3) 6.2 (5.3-8.4) 6.5 (4.4-7.7) 11.7 (9.3-17.7) Relapsed vs refractory = 0.969, alloSCT vs no alloSCT < 0.0001
Duration of response (n = 62), median (range), mo 8.5 (1-84) 10 (1-84) 5 (2-36.9) 5 (1-36.9) Relapsed vs refractory = .3112, alloSCT vs no alloSCT = .4014
Reason for discontinuation of HMA (n = 492), n (%) Relapsed vs refractory = .0905, alloSCT vs no alloSCT < .0001
 Intolerance 31 (6.3) 18 (6.4) 13 (6.2) 2 (3.2)
 No response 136 (27.6) 65 (23) 71 (33.8) 8 (12.7)
 Progression of disease 273 (55.5) 170 (60.3) 103 (49) 24 (38.1)
 End of protocol 45 (9.1) 25 (8.9) 20 (9.5) 29 (46)
 Ongoing treatment, n (%) 7 (1.4) 4 (1.4) 3 (1.4) 0 (0)
Number of lines of therapy after HMA failure (n = 612), median (range) 0 (0-6) 0 (0-5) 0 (0-6) 1 (0-6) Relapsed vs refractory = .6315, alloSCT vs no alloSCT = .0004
AlloSCT after HMA therapy (n = 629), n (%) 37 (5.6) 16 (43.2) 21 (56.8) Relapsed vs refractory = .5108

Inf, infinity; NA, not applicable.